CALCULATION
OF REGISTRATION FEE
|
|
Maximum Aggregate
|
|
Amount of Registration
|
Title of Each Class of Securities Offered
|
|
Offering Price
|
|
Fee
|
Contingent Income Buffered Auto-
|
|
$250,000
|
|
$30.30
|
Callable Securities due 2022
|
|
|
|
|
May 2019
Pricing Supplement No. 1,906
Registration Statement Nos.
333-221595; 333-221595-01
Dated May 28, 2019
Filed pursuant to Rule 424(b)(2)
Morgan Stanley Finance LLC
Structured
Investments
Opportunities in U.S. Equities
Contingent Income Buffered Auto-Callable Securities
due June 3, 2022, With 6-month Initial Non-Call Period
All Payments on the Securities Based on the
Worst Performing of the SPDR
®
S&P
®
Biotech ETF and the VanEck Vectors
®
Gold Miners
ETF
Fully and Unconditionally
Guaranteed by Morgan Stanley
Principal at Risk Securities
The
securities are unsecured obligations of Morgan Stanley Finance LLC (“MSFL”) and are fully and unconditionally guaranteed
by Morgan Stanley. The securities have the terms described in the accompanying product supplement, index supplement and prospectus,
as supplemented or modified by this document. The securities do not provide for the regular payment of interest and provide a
minimum payment at maturity of only 20% of the stated principal amount. Instead, the securities will pay a contingent monthly
coupon
but only if
the determination closing
price of
each of the SPDR
®
S&P
®
Biotech ETF and the VanEck Vectors
®
Gold Miners ETF
, which we refer to as the underlying shares,
is
at or above
80% of its respective initial share price, which we refer to as the coupon barrier level,
on
the related observation date. If, however, the determination closing price of
either of the underlying shares
is less than
its respective coupon barrier level on any observation date, we will pay no interest for the related monthly period. Beginning
after six months, the securities will be automatically redeemed if the determination closing
price of each of the underlying
shares is
greater than or equal to
its respective initial share price
on
any monthly redemption determination date for the early redemption payment equal to the sum of the stated principal amount plus
the related contingent monthly coupon.
No further payments will be made on the securities once they have been redeemed.
At maturity, if
the securities have not previously been redeemed
and the final share price of each of the underlying shares is
greater than or equal to
80% of its respective initial share
price, meaning that
neither
of the underlying shares has declined by an amount greater than the buffer amount of 20%, the
payment at maturity will be the stated principal amount and the related contingent monthly coupon. However, if the final share
price of
either
of the underlying shares is
less than
80% of its respective initial share price, meaning that
either
of the underlying shares has declined by an amount greater than the buffer amount of 20%, investors will lose 1% for every
1% decline in the final share price of the worst performing underlying shares from its initial share price beyond the buffer amount
of 20%.
Accordingly,
i
nvestors in the securities must be willing to accept the risk of losing up to 80% of their initial
investment and also the risk of not receiving any contingent monthly coupons throughout the 3-year term of the securities.
The
securities are for investors who are willing to risk their principal and seek an opportunity to earn interest at a potentially
above-market rate in exchange for the risk of receiving no monthly interest over the entire 3-year term and in exchange for the
possibility of an automatic early redemption prior to maturity. Because the payment of contingent monthly coupons is based on
the worst performing of the underlying shares, the fact that the securities are linked to two underlying shares does not provide
any asset diversification benefits and instead means that a decline in the price of either of the underlying shares below the
relevant coupon barrier level will result in no contingent monthly coupons, even if the other underlying shares closes at or above
its respective coupon barrier level. Because all payments on the securities are based on the worst performing of the underlying
shares, a decline of either of the underlying shares by an amount greater than the buffer amount as of the final observation date
will result in a loss of your investment, even if the other underlying shares has appreciated or has not declined as much. Investors
will not participate in any appreciation of either of the underlying shares. The securities are notes issued as part of MSFL’s
Series A Global Medium-Term Notes program.
All payments are subject to our credit risk. If we default
on our obligations, you could lose some or all of your investment. These securities are not secured obligations and you will not
have any security interest in, or otherwise have any access to, any underlying reference asset or assets.
FINAL TERMS
|
Issuer:
|
Morgan Stanley Finance LLC
|
Guarantor:
|
Morgan Stanley
|
Underlying shares:
|
SPDR
®
S&P
®
Biotech ETF (the “XBI Shares”) and VanEck Vectors
®
Gold Miners ETF (the “GDX Shares”)
|
Aggregate principal amount:
|
$250,000
|
Stated principal amount:
|
$1,000 per security
|
Issue price:
|
$1,000 per security
|
Pricing date:
|
May 28, 2019
|
Original issue date:
|
May 31, 2019 (3 business days after the pricing date)
|
Maturity date:
|
June 3, 2022
|
Early redemption:
|
The securities are not subject to automatic early redemption
until approximately six months after the original issue date.
Following this initial 6-month non-call period, if, on any redemption
determination date, beginning on November 29, 2019, the determination closing price of
each of the underlying shares
is
greater than or equal to its respective initial share price, the securities will be automatically redeemed for an early redemption
payment on the related early redemption date. No further payments will be made on the securities once they have been redeemed.
The securities will not be redeemed early on any early redemption
date if the determination closing price of either of the underlying shares is below its respective initial share price on the related
redemption determination date.
|
Early redemption payment:
|
The early redemption payment will be an amount equal to (i) the stated principal amount for each security you hold
plus
(ii) the contingent monthly coupon with respect to the related observation date.
|
Determination closing price:
|
With respect to each of the underlying shares, the closing price of such underlying shares on any redemption determination date or observation date (other than the final observation date),
times
the adjustment factor on such redemption determination date or observation date, as applicable
|
Redemption determination dates:
|
Monthly, as set forth under “Observation Dates, Redemption Determination Dates, Coupon Payment Dates and Early Redemption Dates” below, subject to postponement for non-trading days and certain market disruption events.
|
Early redemption dates:
|
Starting on December 4, 2019 (approximately six months after the original issue date), monthly. See “Observation Dates, Redemption Determination Dates, Coupon Payment Dates and Early Redemption Dates” below. If any such day is not a business day, that early redemption payment, if payable, will be made on the next succeeding business day and no adjustment will be made to any early redemption payment made on that succeeding business day.
|
Contingent monthly coupon:
|
A
contingent
monthly coupon at an annual rate of 10.20%
(corresponding to approximately $8.50 per month per security) will be paid on the securities on each coupon payment date
but
only if
the determination closing price of
each of the underlying shares
is at or above its respective coupon barrier
level on the related observation date.
If, on any observation date, the determination closing price
of either of the underlying shares is less than its respective coupon barrier level, no contingent monthly coupon will be paid
with respect to that observation date. It is possible that one or both of the underlying shares will remain below their respective
coupon barrier levels for extended periods of time or even throughout the entire 3-year term of the securities so that you will
receive few or no contingent monthly coupons.
|
Coupon barrier level:
|
With respect to the XBI Shares, $65.624, which is equal to 80%
of its initial share price
With respect to the GDX Shares, $16.336, which is equal to 80%
of its initial share price
|
Buffer amount:
|
With respect to each of the underlying shares, 20%. As a result
of the buffer amount of 20%, the price at or above which each of the underlying shares must close on the final observation date
so that investors do not suffer a loss on their initial investment in the securities is as follows:
With respect to the XBI Shares, $65.624, which is equal to 80%
of its initial share price
With respect to the GDX Shares, $16.336, which is equal to 80%
of its initial share price
|
Payment at maturity:
|
If the securities are not redeemed
prior to maturity, investors will receive a payment at maturity determined as follows:
·
If
the final share price of
each of the underlying shares
is
greater than or equal to
80% of its respective initial
share price, meaning that
neither
of the underlying shares has decreased by an amount greater than the buffer amount of
20% from its respective initial share price: the stated principal amount and the contingent monthly coupon with respect to the
final observation date
·
If
the final share price of
either of the underlying shares is less than
80% of its respective initial share price, meaning
that
either
of the underlying shares has decreased by an amount greater than the buffer amount of 20% from its respective
initial share price:
$1,000 + [$1,000 x (share
percent change of the worst performing underlying shares + 20%)]
Under these circumstances, the payment at maturity will be
less than the stated principal amount of $1,000. However, under no circumstances will the securities pay less than the minimum
payment at maturity of $200 per security.
|
|
Terms continued on the following page
|
Agent:
|
Morgan Stanley & Co. LLC (“MS & Co.”), an affiliate of MSFL and a wholly owned subsidiary of Morgan Stanley. See “Supplemental information regarding plan of distribution; conflicts of interest.”
|
Estimated value on the pricing date:
|
$952.40 per security. See “Investment Summary” beginning on page 3.
|
Commissions and issue price:
|
Price to public
|
Agent’s commissions
(1)
|
Proceeds to us
(2)
|
Per security
|
$1,000
|
$26.25
|
$973.75
|
Total
|
$250,000
|
$6,562.50
|
$243,437.50
|
|
(1)
|
Selected dealers
and their financial advisors will collectively receive from the agent, MS & Co.,
a fixed sales commission of $26.25 for each security they sell. See “Supplemental
information regarding plan of distribution; conflicts of interest.” For additional
information, see “Plan of Distribution (Conflicts of Interest)” in the accompanying
product supplement.
|
|
(2)
|
See “Use
of proceeds and hedging” on page 26.
|
The securities involve risks
not associated with an investment in ordinary debt securities. See “Risk Factors” beginning on page 10.
The Securities and Exchange Commission and state securities
regulators have not approved or disapproved these securities, or determined if this document or the accompanying product supplement,
index supplement and prospectus is truthful or complete. Any representation to the contrary is a criminal offense.
The securities are not deposits or savings accounts and are
not insured by the Federal Deposit Insurance Corporation or any other governmental agency or instrumentality, nor are they obligations
of, or guaranteed by, a bank.
You should read this document together with the related product
supplement, index supplement and prospectus, each of which can be accessed via the hyperlinks below. Please also see “Additional
Terms of the Securities” and “Additional Information About the Securities” at the end of this document.
As used in this document, “we,” “us”
and “our” refer to Morgan Stanley or MSFL, or Morgan Stanley and MSFL collectively, as the context requires.
Product
Supplement for Auto-Callable Securities dated November 16, 2017
Index
Supplement dated November 16, 2017
Prospectus
dated November 16, 2017
Morgan
Stanley Finance LLC
Contingent Income Buffered Auto-Callable Securities
due June 3, 2022, With 6-month Initial Non-Call Period
All Payments on the Securities Based on the
Worst Performing of the SPDR
®
S&P
®
Biotech ETF and the VanEck Vectors
®
Gold Miners
ETF
Principal at Risk Securities
Terms continued from previous page:
|
Initial share price:
|
With respect to the XBI Shares, $82.03, which is its closing
price on the pricing date
With respect to the GDX Shares, $20.42, which is its closing
price on the pricing date
|
Coupon payment dates:
|
Monthly, as set forth under “Observation Dates, Redemption Determination Dates, Coupon Payment Dates and Early Redemption Dates” below. If any such day is not a business day, that coupon payment will be made on the next succeeding business day and no adjustment will be made to any coupon payment made on that succeeding business day;
provided
that the contingent monthly coupon, if any, with respect to the final observation date shall be paid on the maturity date.
|
Observation dates:
|
Monthly, as set forth under “Observation Dates, Redemption Determination Dates, Coupon Payment Dates and Early Redemption Dates” below, subject to postponement for non-trading days and certain market disruption events. We also refer to May 31, 2022, which is the third scheduled business day preceding the scheduled maturity date, as the final observation date.
|
Final share price:
|
With respect to each of the underlying shares, the closing price of such underlying shares on the final observation date
times
the adjustment factor on such date
|
Minimum payment at maturity:
|
$200 per security (20% of the stated principal amount)
|
Adjustment factor:
|
With respect to each of the underlying shares, 1.0, subject to adjustment in the event of certain events affecting such underlying shares
|
Worst performing underlying shares:
|
The underlying shares with the larger percentage decrease from the respective initial share price to the respective final share price
|
Share percent change:
|
With respect to each of the underlying shares: (final share price – initial share price) / initial share price
|
CUSIP / ISIN:
|
61768D7Z2 / US61768D7Z21
|
Listing:
|
The securities will not be listed on any securities exchange.
|
Observation
Dates, Redemption Determination Dates, Coupon Payment Dates and Early Redemption Dates
Observation Dates / Redemption Determination Dates
|
Coupon Payment Dates / Early Redemption Dates
|
6/28/2019*
|
7/3/2019*
|
7/29/2019*
|
8/1/2019*
|
8/28/2019*
|
9/3/2019*
|
9/30/2019*
|
10/3/2019*
|
10/28/2019*
|
10/31/2019*
|
11/29/2019
|
12/4/2019
|
12/30/2019
|
1/3/2020
|
1/28/2020
|
1/31/2020
|
2/28/2020
|
3/4/2020
|
3/30/2020
|
4/2/2020
|
4/28/2020
|
5/1/2020
|
5/28/2020
|
6/2/2020
|
6/29/2020
|
7/2/2020
|
7/28/2020
|
7/31/2020
|
8/28/2020
|
9/2/2020
|
9/28/2020
|
10/1/2020
|
10/28/2020
|
11/2/2020
|
11/30/2020
|
12/3/2020
|
12/28/2020
|
12/31/2020
|
1/28/2021
|
2/2/2021
|
2/26/2021
|
3/3/2021
|
3/29/2021
|
4/1/2021
|
4/28/2021
|
5/3/2021
|
5/28/2021
|
6/3/2021
|
6/28/2021
|
7/1/2021
|
7/28/2021
|
8/2/2021
|
8/30/2021
|
9/2/2021
|
9/28/2021
|
10/1/2021
|
10/28/2021
|
11/2/2021
|
11/29/2021
|
12/2/2021
|
12/28/2021
|
12/31/2021
|
1/28/2022
|
2/2/2022
|
2/28/2022
|
3/3/2022
|
3/28/2022
|
3/31/2022
|
4/28/2022
|
5/3/2022
|
5/31/2022 (final observation date)
|
6/3/2022 (maturity date)
|
* The securities are not subject to automatic early redemption
until the sixth coupon payment date, which is December 4, 2019.
Morgan Stanley Finance LLC
Contingent Income Buffered Auto-Callable Securities due June 3, 2022, With 6-month Initial Non-Call Period
All Payments on the Securities Based on the Worst Performing of the SPDR
®
S&P
®
Biotech ETF and the VanEck Vectors
®
Gold Miners ETF
Principal at Risk Securities
Investment Summary
Contingent Income Buffered Auto-Callable Securities
Principal at Risk Securities
Contingent Income Buffered Auto-Callable Securities due June
3, 2022, With 6-month Initial Non-Call Period All Payments on the Securities Based on the Worst Performing of the SPDR
®
S&P
®
Biotech ETF and the VanEck Vectors
®
Gold Miners ETF (the “securities”) do not
provide for the regular payment of interest. Instead, the securities will pay a contingent monthly coupon
but only if
the
determination closing price of
each of the SPDR
®
S&P
®
Biotech ETF and the VanEck Vectors
®
Gold Miners ETF
, which we refer to as the underlying shares, is
at or above
80% of its respective initial share price,
which we refer to as the coupon barrier level, on the related observation date. If, however, the determination closing price of
either of the underlying shares
is less than its respective coupon barrier level on any observation date, we will pay no
interest for the related monthly period. Beginning after six months, the securities will be automatically redeemed if the determination
closing price of each of the underlying shares is
greater than or equal to
its respective initial share price on any monthly
redemption determination date for the early redemption payment equal to the sum of the stated principal amount plus the related
contingent monthly coupon. No further payments will be made on the securities once they have been redeemed. At maturity, if the
securities have not previously been redeemed and the final share price of each of the underlying shares is
greater than or equal
to
80% of its respective initial share price, meaning that
neither
of the underlying shares has declined by an amount
greater than the buffer amount of 20%, the payment at maturity will be the stated principal amount and the related contingent monthly
coupon. However, if the final share price of
either
of the underlying shares
is less than
80% of its respective initial
share price, meaning that
either
of the underlying shares has declined by an amount greater than the buffer amount of 20%,
investors will lose 1% for every 1% decline in the final share price of the worst performing underlying shares from its initial
share price beyond the buffer amount of 20%.
Accordingly,
i
nvestors in the securities must be willing to accept the risk
of losing up to 80% of their initial investment and also the risk of not receiving any contingent monthly coupons throughout the
3-year term of the securities.
Investors will not participate in any appreciation in the price of either of the underlying
shares.
Maturity:
|
Approximately 3 years
|
Contingent monthly coupon:
|
A
contingent
monthly coupon at an annual rate of 10.20%
(corresponding to approximately $8.50 per month per security) will be paid on the securities on each coupon payment date
but
only if
the determination closing price of
each of the underlying shares
is at or above its respective coupon barrier
level on the related observation date.
If on any observation date, the determination closing price
of either of the underlying shares is less than its respective coupon barrier level, we will pay no coupon for the applicable monthly
period.
|
Automatic early redemption monthly starting after six months:
|
The securities are not subject to automatic early redemption until approximately six months after the original issue date. Following this initial 6-month non-call period, if the determination closing price of
each of the underlying shares
is greater than or equal to its respective initial share price on any monthly redemption determination date, beginning on November 29, 2019, the securities will be automatically redeemed for an early redemption payment equal to the stated principal amount
plus
the contingent monthly coupon with respect to the related observation date. No further payments will be made on the securities once they have been redeemed.
|
Payment at maturity:
|
If the securities have not previously been redeemed and the final
share price of
each of the underlying shares
is
greater than or equal to
80% of its respective initial share price,
meaning that
neither
of the underlying shares has declined by an amount greater than the buffer amount of 20%, the payment
at maturity will be the stated principal amount and the related contingent monthly coupon.
If the final share price of
either
of the underlying shares
is
less than
80% of its respective initial share price, meaning that
either
of the underlying shares has declined
by an amount greater than the buffer amount of 20%, investors will lose 1% for every 1% decline in the final share price of the
worst performing underlying shares from its initial share price beyond the buffer amount of 20%. Under these circumstances, the
payment at maturity will be less than the stated principal amount of the securities.
However, under no circumstances will the
securities pay less than the minimum payment at maturity of $200 per security.
Accordingly,
i
nvestors in the securities
must be willing to accept the
|
Morgan Stanley Finance LLC
Contingent Income Buffered Auto-Callable Securities due June 3, 2022, With 6-month Initial Non-Call Period
All Payments on the Securities Based on the Worst Performing of the SPDR
®
S&P
®
Biotech ETF and the VanEck Vectors
®
Gold Miners ETF
Principal at Risk Securities
|
risk of losing up to 80% of their initial investment.
|
Morgan Stanley Finance LLC
Contingent Income Buffered Auto-Callable Securities due June 3, 2022, With 6-month Initial Non-Call Period
All Payments on the Securities Based on the Worst Performing of the SPDR
®
S&P
®
Biotech ETF and the VanEck Vectors
®
Gold Miners ETF
Principal at Risk Securities
The original issue price of each security is
$1,000. This price includes costs associated with issuing, selling, structuring and hedging the securities, which are borne by
you, and, consequently, the estimated value of the securities on the pricing date is less than $1,000. We estimate that the value
of each security on the pricing date is $952.40.
What goes into the estimated value on the pricing date?
In valuing the securities on the pricing date,
we take into account that the securities comprise both a debt component and a performance-based component linked to the underlying
shares. The estimated value of the securities is determined using our own pricing and valuation models, market inputs and assumptions
relating to the underlying shares, instruments based on the underlying shares, volatility and other factors including current and
expected interest rates, as well as an interest rate related to our secondary market credit spread, which is the implied interest
rate at which our conventional fixed rate debt trades in the secondary market.
What determines the economic terms of the securities?
In determining the economic terms of the securities,
including the contingent monthly coupon rate, the coupon barrier levels and the buffer amount, we use an internal funding rate,
which is likely to be lower than our secondary market credit spreads and therefore advantageous to us. If the issuing, selling,
structuring and hedging costs borne by you were lower or if the internal funding rate were higher, one or more terms of the securities
would be more favorable to you.
What is the relationship between the estimated value on the
pricing date and the secondary market price of the securities?
The price at which MS & Co. purchases the
securities in the secondary market, absent changes in market conditions, including those related to the underlying shares, may
vary from, and be lower than, the estimated value on the pricing date, because the secondary market price takes into account our
secondary market credit spread as well as the bid-offer spread that MS & Co. would charge in a secondary market transaction
of this type and other factors. However, because the costs associated with issuing, selling, structuring and hedging the securities
are not fully deducted upon issuance, for a period of up to 6 months following the issue date, to the extent that MS & Co.
may buy or sell the securities in the secondary market, absent changes in market conditions, including those related to the underlying
shares, and to our secondary market credit spreads, it would do so based on values higher than the estimated value. We expect that
those higher values will also be reflected in your brokerage account statements.
MS & Co. may, but is not obligated to, make a market in the
securities and, if it once chooses to make a market, may cease doing so at any time.
Morgan Stanley Finance LLC
Contingent Income Buffered Auto-Callable Securities due June 3, 2022, With 6-month Initial Non-Call Period
All Payments on the Securities Based on the Worst Performing of the SPDR
®
S&P
®
Biotech ETF and the VanEck Vectors
®
Gold Miners ETF
Principal at Risk Securities
Key Investment Rationale
The securities do not provide for the regular payment of interest.
Instead, the securities will pay a contingent monthly coupon
but only if
the determination closing price of
each of the
underlying shares
is
at or above its respective coupon barrier level
on the related observation date. The securities
have been designed for investors who are willing to forgo market floating interest rates and risk the loss of principal and accept
the risk of receiving few or no coupon payments for the entire 3-year term of the securities in exchange for an opportunity to
earn interest at a potentially above-market rate if both of the underlying shares close at or above their respective coupon barrier
levels on each monthly observation date, unless the securities are redeemed early. The following scenarios are for illustration
purposes only to demonstrate how the coupon and the payment at maturity (if the securities have not previously been redeemed) are
calculated, and do not attempt to demonstrate every situation that may occur. Accordingly, the securities may or may not be redeemed,
the contingent monthly coupon may be payable in none of, or some but not all of, the monthly periods during the 3-year term of
the securities, and the payment at maturity may be up to 80% less than the stated principal amount of the securities.
Scenario 1: The securities are redeemed prior to maturity
|
This scenario assumes that, prior to early redemption, each of
the underlying shares closes at or above its respective coupon barrier level on some monthly observation dates, but one or both
of the underlying shares close below the coupon barrier level(s) on the others. Investors receive the contingent monthly coupon
for the monthly periods for which the determination closing price of each of the underlying shares is at or above its respective
coupon barrier level on the related observation date, but not for the monthly periods for which the determination closing price
of either of the underlying shares is below the respective coupon barrier level(s) on the related observation date.
Beginning after six months, when each of the underlying shares
closes at or above its respective initial share price on a monthly redemption determination date, the securities will be automatically
redeemed for the stated principal amount
plus
the contingent monthly coupon with respect to the related observation date.
|
Scenario 2: The securities are not redeemed prior to maturity, and investors receive principal back at maturity
|
This scenario assumes that each of the underlying shares closes at or above its respective coupon barrier level on some monthly observation dates, but one or both of the underlying shares close below the respective coupon barrier level(s) on the others, and at least one of the underlying shares closes below its initial share price on every monthly redemption determination date. Consequently, the securities are not redeemed early, and investors receive the contingent monthly coupon for the monthly periods for which the determination closing price of each of the underlying shares is at or above its respective coupon barrier level on the related observation date, but not for the monthly periods for which the determination closing price of one or both of the underlying shares is below the respective coupon barrier level(s) on the related observation date. On the final observation date, each of the underlying shares closes at or above 80% of its respective initial share price, meaning that neither of the underlying shares has declined by an amount greater than the buffer amount of 20%. At maturity investors will receive the stated principal amount and the related contingent monthly coupon.
|
Morgan Stanley Finance LLC
Contingent Income Buffered Auto-Callable Securities due June 3, 2022, With 6-month Initial Non-Call Period
All Payments on the Securities Based on the Worst Performing of the SPDR
®
S&P
®
Biotech ETF and the VanEck Vectors
®
Gold Miners ETF
Principal at Risk Securities
Scenario 3: The securities are not redeemed prior to maturity, and investors suffer a loss of principal at maturity
|
This scenario assumes that each of the underlying shares closes at or above its respective coupon barrier level on some monthly observation dates, but one or both of the underlying shares close below the respective coupon barrier level(s) on the others, and at least one of the underlying shares closes below its initial share price on every monthly redemption determination date. Consequently, the securities are not redeemed early, and investors receive the contingent monthly coupon for the monthly periods for which the determination closing price of each of the underlying shares is greater than or equal to its respective coupon barrier level on the related observation date, but not for the monthly periods for which the determination closing price of one or both of the underlying shares is below the respective coupon barrier level(s) on the related observation date. On the final observation date, at least one of the underlying shares closes below 80% of its respective initial share price, meaning that such underlying shares has declined by an amount greater than the buffer amount of 20%. At maturity, investors will lose 1% for every 1% decline in the final share price of the worst performing underlying shares from its initial share price beyond the buffer amount of 20%. Under these circumstances, the payment at maturity will be less than the stated principal amount. Investors may lose up to 80% of their investment in the securities. No coupon will be paid at maturity in this scenario.
|
Morgan Stanley Finance LLC
Contingent Income Buffered Auto-Callable Securities due June 3, 2022, With 6-month Initial Non-Call Period
All Payments on the Securities Based on the Worst Performing of the SPDR
®
S&P
®
Biotech ETF and the VanEck Vectors
®
Gold Miners ETF
Principal at Risk Securities
Hypothetical Examples
The following hypothetical examples illustrate how to determine
whether a contingent monthly coupon is paid with respect to an observation date and how to calculate the payment at maturity, assuming
the securities are not redeemed prior to maturity. The following examples are for illustrative purposes only. Whether you receive
a contingent monthly coupon will be determined by reference to the determination closing price of each of the underlying shares
on each monthly observation date, and the amount you will receive at maturity will be determined by reference to the final share
price of each of the underlying shares on the final observation date. The actual initial share price and coupon barrier level for
each of the underlying shares are set forth on the cover of this document. All payments on the securities are subject to our credit
risk. The below examples are based on the following terms:
Contingent Monthly Coupon:
|
10.20% per annum (corresponding to approximately $8.50 per month
per security)
1
With respect to each coupon payment date, a contingent monthly
coupon is paid but only if the determination closing price of each of the underlying shares is at or above its respective coupon
barrier level on the related observation date.
|
Payment at Maturity (if the securities are not redeemed prior to maturity):
|
If the final share price of
each
of the underlying shares
is
greater than or equal to
80% of its respective initial share price: the stated principal amount and the contingent monthly
coupon with respect to the final observation date.
If the final share price of
either
of the underlying shares
is
less than
80% of its respective initial share price:
$1,000 + [$1,000 x (share percent change of the worst
performing underlying shares + 20%)]
|
Stated Principal Amount:
|
$1,000
|
Minimum Payment at Maturity:
|
$200 per security
|
Hypothetical Initial Share Price:
|
With respect to the XBI Shares: $90.00
With respect to the GDX Shares: $20.00
|
Hypothetical Coupon Barrier Level:
|
With respect to the XBI Shares: $72.00, which is 80% of its hypothetical
initial share price
With respect to the GDX Shares: $16.00, which is 80% of its hypothetical
initial share price
|
Buffer Amount:
|
With respect to each of the underlying shares: 20%
|
1
The actual contingent monthly
coupon will be an amount determined by the calculation agent based on the number of days in the applicable payment period, calculated
on a 30/360 day-count basis. The hypothetical contingent monthly coupon rate of $8.50 is used in these examples for ease of analysis.
How to determine whether a contingent monthly
coupon is payable with respect to an observation date:
|
Determination Closing Price
|
Hypothetical Contingent Monthly Coupon
|
|
XBI Shares
|
GDX Shares
|
|
Hypothetical Observation Date 1
|
$75.00 (
at or above
its coupon barrier level)
|
$18.00 (
at or above
its coupon barrier level)
|
$8.50
|
Hypothetical Observation Date 2
|
$78.00 (
at or above
its coupon barrier level)
|
$13.50 (
below
its coupon barrier level)
|
$0
|
Hypothetical Observation Date 3
|
$65.50 (
below
its coupon barrier level)
|
$17.50 (
at or above
its coupon barrier level)
|
$0
|
Hypothetical Observation Date 4
|
$60.00 (
below
its coupon barrier level)
|
$14.00 (
below
its coupon barrier level)
|
$0
|
On hypothetical observation date 1, each of the underlying shares
closes at or above its respective coupon barrier level. Therefore, a contingent monthly coupon of $8.50 is paid on the relevant
coupon payment date.
On each of hypothetical observation dates 2 and 3, one of the
underlying shares closes at or above its respective coupon barrier level but the other underlying shares closes below its respective
coupon barrier level. Therefore, no contingent monthly coupon is paid on the relevant coupon payment date.
On hypothetical observation date 4, each of the underlying shares
closes below its respective coupon barrier level and accordingly no contingent monthly coupon is paid on the relevant coupon payment
date.
You will not receive a contingent monthly coupon on any coupon
payment date if the determination closing price of either of the underlying shares is below its respective coupon barrier level
on the related observation date.
Morgan Stanley Finance LLC
Contingent Income Buffered Auto-Callable Securities due June 3, 2022, With 6-month Initial Non-Call Period
All Payments on the Securities Based on the Worst Performing of the SPDR
®
S&P
®
Biotech ETF and the VanEck Vectors
®
Gold Miners ETF
Principal at Risk Securities
How to calculate the payment at maturity:
In the following examples, one or both of the underlying shares
close below the respective initial share price(s) on each redemption determination date, and, consequently, the securities are
not automatically redeemed prior to, and remain outstanding until, maturity.
|
Final Share Price
|
Payment at Maturity
|
|
XBI Shares
|
GDX Shares
|
|
Example 1:
|
$95.00 (
at or above
80% of initial share price)
|
$28.50 (
at or above
80% of initial share price)
|
$1,008.50 (the stated principal amount and the contingent monthly coupon with respect to the final observation date)
|
Example 2:
|
$22.50 (
below
80% of initial share price)
|
$30.00 (
at or above
80% of initial share price)
|
$1,000 + [$1,000 x (share percent change of the worst performing underlying shares + 20%)]
= $1,000 + [$1,000 x (-75% + 20%)]
= $1,000 + ($1,000 x -55.00%) = $450
|
Example 3:
|
$27.00 (
below
80% of initial share price)
|
$3.00 (
below
80% of initial share price)
|
$1,000 + [$1,000 x (share percent change of the worst performing underlying shares + 20%)]
= $1,000 + [$1,000 x (-85% + 20%)]
= $1,000 + ($1,000 x -65.00%) = $350
|
|
|
|
|
|
In example 1, the final share prices of each of the underlying
shares is at or above 80% of its initial share price. Therefore, investors receive at maturity the stated principal amount of the
securities and the contingent monthly coupon with respect to the final observation date. However, investors do not participate
in any appreciation of either of the underlying shares.
In example 2, the final share price of one of the underlying
shares is at or above 80% of its initial share price, but the final share price of the other underlying shares is below 80% of
its initial share price. Therefore, investors are exposed to the downside performance of the XBI Shares, which are the worst performing
underlying shares in this example, and investors lose 1% of principal for every 1% decline in the final share price of the XBI
Shares from its initial share price beyond the buffer amount of 20%. The payment at maturity in this example is equal to $450 per
security. Investors do not receive the contingent monthly coupon for the final observation date.
In example 3, the final share prices of both of the underlying
shares are below 80% of their initial share prices. Therefore, investors are exposed to the downside performance of the GDX Shares,
which are the worst performing underlying shares in this example, and investors lose 1% of principal for every 1% decline in the
final share price of the GDX Shares from its initial share price beyond the buffer amount of 20%. The payment at maturity in this
example is equal to $350 per security. Investors do not receive the contingent monthly coupon for the final observation date.
If the final share price of EITHER of the underlying shares
is below 80% of its initial share price, you will be exposed to the downside performance of the worst performing underlying shares
at maturity, and your payment at maturity will be less than the stated principal amount per security. Under these circumstances,
you will lose some, and up to 80%, of your investment in the securities.
Morgan Stanley Finance LLC
Contingent Income Buffered Auto-Callable Securities due June 3, 2022, With 6-month Initial Non-Call Period
All Payments on the Securities Based on the Worst Performing of the SPDR
®
S&P
®
Biotech ETF and the VanEck Vectors
®
Gold Miners ETF
Principal at Risk Securities
Risk Factors
The
following is a list of certain key risk factors for investors in the securities. For further discussion of these and other risks,
you should read the section entitled “Risk Factors” in the accompanying product supplement, index supplement and prospectus.
We also urge you to consult with your investment, legal, tax, accounting and other advisers
in connection with your
investment in the securities
.
|
§
|
The
securities provide a minimum payment at maturity of only 20% of your principal
.
The
terms of the securities differ from those of ordinary debt securities in that they provide
a minimum payment at maturity of only 20% of the stated principal amount at maturity.
If the securities have not been automatically redeemed prior to maturity and if the final
share price of
either
of the underlying shares is
less than
80% of its
respective initial share price, meaning that either of the underlying shares has declined
by an amount greater than the buffer amount of 20%, you will lose 1% for every 1% decline
in the final share price of the worst performing underlying shares from its initial share
price beyond the buffer amount of 20%. In this case, the payment at maturity will be
less than the stated principal amount.
You could lose up to 80% of your investment
in the securities.
|
|
§
|
The
securities do not provide for the regular payment of interest and may pay no interest
over the entire term of the securities
.
The terms of the securities differ
from those of ordinary debt securities in that they do not provide for the regular payment
of interest. Instead, the securities will pay a contingent monthly coupon
but only
if
the determination closing price of
each of the underlying shares
is
at
or above
80% of its respective initial share price, which we refer to as the coupon
barrier level, on the related observation date. If, on the other hand, the determination
closing price of
either of the underlying shares
is lower than its respective
coupon barrier level on the relevant observation date for any interest period, we will
pay no coupon on the applicable coupon payment date. It is possible that the determination
closing price of one or both of the underlying shares could remain below the respective
coupon barrier level(s) for extended periods of time or even throughout the entire 3-year
term of the securities so that you will receive few or no contingent monthly coupons.
If you do not earn sufficient contingent monthly coupons over the term of the securities,
the overall return on the securities may be less than the amount that would be paid on
a conventional debt security of ours of comparable maturity.
|
|
§
|
You
are exposed to the price risk of each of the underlying shares, with respect to both
the contingent monthly coupons, if any, and the payment at maturity
.
Your
return on the securities is not linked to a basket consisting of each of the underlying
shares. Rather, it will be contingent upon the independent performance of each of the
underlying shares. Unlike an instrument with a return linked to a basket of underlying
assets, in which risk is mitigated and diversified among all the components of the basket,
you will be exposed to the risks related to each of the underlying shares. Poor performance
by
either
of the underlying shares over
the term of the securities may negatively affect your return and will not be offset or
mitigated by any positive performance by the other underlying shares. To receive
any
contingent monthly coupons,
each of the
underlying shares
must close at or above its respective
coupon barrier level on the applicable observation date. In addition, if
either
of the underlying shares has declined to below
80% of its respective initial share price as of the final observation date,
meaning that either of the underlying shares has declined by an amount greater than the
buffer amount of 20%, you will lose 1% for every 1% decline in the final share price
of the worst performing underlying shares from its initial share price beyond the buffer
amount of 20%
,
even if the other underlying shares has appreciated or has not declined as much. Under
this scenario, the value of any such payment will be less than the stated principal amount.
Accordingly, your investment is subject to the price risk of each of the underlying shares.
|
|
§
|
Investing in the securities exposes investors to risks associated with investments in securities with a concentration in
the biotechnology sector.
The stocks included in the S&P Biotechnology Select Industry
TM
Index and that are
generally tracked by the SPDR
®
S&P
®
Biotech ETF are stocks of companies primarily engaged in
research, development, manufacturing and/or marketing of products based on genetic analysis and genetic engineering. Because the
value of the securities is linked to the performance of the underlying shares, an investment in the securities exposes investors
to risks associated with investments in securities with a concentration in the biotechnology sector. Industry-specific risks to
which companies in the biotechnology sector are subject may include the following:
|
|
o
|
After spending heavily on research and development, their products or services may not prove commercially successful or may
become obsolete quickly;
|
|
o
|
The biotechnology industry may be subject to greater governmental regulation than other industries, and changes in governmental
policies and the need for regulatory approvals may have a material adverse effect on the industry;
|
Morgan Stanley Finance LLC
Contingent Income Buffered Auto-Callable Securities due June 3, 2022, With 6-month Initial Non-Call Period
All Payments on the Securities Based on the Worst Performing of the SPDR
®
S&P
®
Biotech ETF and the VanEck Vectors
®
Gold Miners ETF
Principal at Risk Securities
|
o
|
Companies in the biotechnology industry are subject to risks arising from new technologies and competitive pressures; and
|
|
o
|
Companies in the biotechnology industry are heavily dependent on patents and intellectual property rights. The loss or impairment
of these rights may adversely affect the profitability of these companies.
|
|
o
|
The XBI Shares may be subject to increased price volatility as it is linked to a single industry, market or sector and may
be more susceptible to adverse economic, market, political or regulatory occurrences affecting that industry, market or sector.
The price of the XBI Shares may be, and has recently been, volatile, and we can give you no assurance that the volatility will
lessen.
|
|
§
|
Investing in the securities exposes investors to risks associated with investments in securities with a concentration in
the gold and silver mining industry.
The securities are subject to certain risks applicable to the gold and silver mining industry.
The stocks included in the NYSE Arca Gold Miners Index and that are generally tracked by the GDX Shares are stocks of companies
primarily engaged in the mining of gold or silver. The underlying shares may be subject to increased price volatility as they are
linked to a single industry, market or sector and may be more susceptible to adverse economic, market, political or regulatory
occurrences affecting that industry, market or sector.
|
Because the GDX Shares primarily
invests in stocks, American Depositary Receipts (“ADRs”) and Global Depositary Receipts (“GDRs”) of companies
that are involved in the gold mining industry, the underlying shares are subject to certain risks associated with such companies.
Competitive pressures may have a
significant effect on the financial condition of companies in the gold mining industry. Also, gold mining companies are highly
dependent on the price of gold. Gold prices are subject to volatile price movements over short periods of time and are affected
by numerous factors. These include economic factors, including, among other things, the structure of and confidence in the global
monetary system, expectations of the future rate of inflation, the relative strength of, and confidence in, the U.S. dollar (the
currency in which the price of gold is generally quoted), interest rates and gold borrowing and lending rates, and global or regional
economic, financial, political, regulatory, judicial or other events. Gold prices may also be affected by industry factors such
as industrial and jewelry demand, lending, sales and purchases of gold by the official sector, including central banks and other
governmental agencies and multilateral institutions which hold gold, levels of gold production and production costs, and short-term
changes in supply and demand because of trading activities in the gold market.
The GDX Shares invests to a lesser
extent in stocks, ADRs and GDRs of companies involved in the silver mining industry. Silver mining companies are highly dependent
on the price of silver. Silver prices can fluctuate widely and may be affected by numerous factors. These include general economic
trends, technical developments, substitution issues and regulation, as well as specific factors including industrial and jewelry
demand, expectations with respect to the rate of inflation, the relative strength of the U.S. dollar (the currency in which the
price of silver is generally quoted) and other currencies, interest rates, central bank sales, forward sales by producers, global
or regional political or economic events, and production costs and disruptions in major silver producing countries such as Mexico
and Peru. The supply of silver consists of a combination of new mine production and existing stocks of bullion and fabricated silver
held by governments, public and private financial institutions, industrial organizations and private individuals. In addition,
the price of silver has on occasion been subject to very rapid short-term changes due to speculative activities. From time to time,
above-ground inventories of silver may also influence the market. The major end-uses for silver include industrial applications,
jewelry, photography and silverware.
|
§
|
The prices of the GDX Shares are subject to currency exchange risk.
Because the prices of the GDX Shares are related
to the U.S. dollar value of stocks underlying the NYSE Arca Gold Miners Index, holders of the securities will be exposed to currency
exchange rate risk with respect to the currencies in which such component securities trade. Exchange rate movements for a particular
currency are volatile and are the result of numerous factors including the supply of, and the demand for, those currencies, as
well as relevant government policy, intervention or actions, but are also influenced significantly from time to time by political
or economic developments, and by macroeconomic factors and speculative actions related to the relevant region. An investor’s
net exposure will depend on the extent to which the currencies of the component securities strengthen or weaken against the U.S.
dollar and the relative weight of each currency. If, taking into account such weighting, the dollar strengthens against the currencies
of the component securities represented in the NYSE Arca Gold Miners Index, the price of the GDX Shares will be adversely affected.
|
|
§
|
The contingent monthly coupon, if any, is based only on the determination closing prices of the underlying shares on the
related monthly observation date at the end of the related interest period
.
Whether the contingent monthly coupon will be paid on any coupon payment date will be determined at the end of the relevant
interest period based on the
|
Morgan Stanley Finance LLC
Contingent Income Buffered Auto-Callable Securities due June 3, 2022, With 6-month Initial Non-Call Period
All Payments on the Securities Based on the Worst Performing of the SPDR
®
S&P
®
Biotech ETF and the VanEck Vectors
®
Gold Miners ETF
Principal at Risk Securities
determination closing price of each
of the underlying shares on the relevant monthly observation date. As a result, you will not know whether you will receive the
contingent monthly coupon on any coupon payment date until near the end of the relevant interest period. Moreover, because the
contingent monthly coupon is based solely on the price of each of the underlying shares on monthly observation dates, if the determination
closing price of either of the underlying shares on any observation date is below its respective coupon barrier level, you will
receive no coupon for the related interest period even if the price(s) of one or both of the underlying shares were higher on other
days during that interest period.
|
§
|
Investors will not participate in any appreciation in the price of either of the underlying shares.
Investors will not
participate in any appreciation in the price of the underlying shares from their initial share prices, and the return on the securities
will be limited to the contingent monthly coupon that is paid with respect to each observation date on which each determination
closing price is greater than or equal to its respective coupon barrier level, if any.
|
|
§
|
The market price will be influenced by many unpredictable factors.
Several factors, many of which are beyond our control, will influence the value of the securities
in the secondary market and the price at which MS & Co. may be willing to purchase or sell the securities in the secondary
market. We expect that generally the level of interest rates available in the market and the prices of the
underlying
shares
on any day, including in relation to the respective
coupon barrier levels, will affect the value of the securities more than any other factors. Other factors that may influence the
value of the securities include:
|
|
o
|
the trading price and volatility (frequency and magnitude of changes in value) of the underlying shares and the stocks constituting
their respective share underlying indices,
|
|
o
|
whether the determination closing price of either of the underlying shares has been below its respective coupon barrier level
on any observation date,
|
|
o
|
dividend rates on the stocks constituting the share underlying indices,
|
|
o
|
geopolitical conditions and economic, financial, political, regulatory or judicial events that affect the underlying shares
or equity markets generally and which may affect the prices of the underlying shares,
|
|
o
|
the time remaining until the securities mature,
|
|
o
|
interest and yield rates in the market,
|
|
o
|
the availability of comparable instruments,
|
|
o
|
the occurrence of certain events affecting the underlying shares that may or may not require an adjustment to the adjustment
factor,
|
|
o
|
the composition of the underlyings and changes in the constituents of the underlying shares, and
|
|
o
|
any actual or anticipated changes in our credit ratings or credit spreads.
|
Some
or all of these factors will influence the price that you will receive if you sell your securities prior to maturity. For example,
you may have to sell your securities at a substantial discount from the stated principal amount of $1,000 per security if the price
of either of the underlying shares at the time of sale is near or below its coupon barrier level or if market interest rates rise.
The
price of any or both of the underlying shares may be, and have recently been, volatile, and we can give you no assurance that the
volatility will lessen.
The prices of one or both of the underlying shares may decrease and be below the respective coupon
barrier level(s) on each observation date so that you will receive no return on your investment, and one or both of the underlying
shares may decline by an amount greater than the buffer amount as of the final observation date so that you lose some or a significant
portion of your initial investment in the securities. There can be no assurance that the closing price of each of the underlying
shares will be at or above their respective coupon barrier level on any observation date so that you will receive a coupon payment
on the securities for the applicable interest period, or that neither of the underlying shares will decline by an amount greater
than the buffer amount of 20% as of the final observation date so that you do not suffer a loss on your initial investment in the
securities.
See
“
SPDR
®
S&P
®
Biotech ETF Overview”
and
“
VanEck Vectors
®
Gold Miners ETF Overview
”
below
.
|
§
|
The securities are subject to our credit risk, and any actual or anticipated changes to our credit ratings or credit spreads
may adversely affect the market value of the securities.
You are dependent on our ability to pay all amounts due on the securities
on each coupon payment date, upon automatic redemption and at maturity and therefore you are subject to our credit risk. The securities
are not guaranteed by any other entity. If we default on our obligations under the
|
Morgan Stanley Finance LLC
Contingent Income Buffered Auto-Callable Securities due June 3, 2022, With 6-month Initial Non-Call Period
All Payments on the Securities Based on the Worst Performing of the SPDR
®
S&P
®
Biotech ETF and the VanEck Vectors
®
Gold Miners ETF
Principal at Risk Securities
securities, your investment would
be at risk and you could lose some or all of your investment. As a result, the market value of the securities prior to maturity
will be affected by changes in the market’s view of our creditworthiness. Any actual or anticipated decline in our credit
ratings or increase in the credit spreads charged by the market for taking our credit risk is likely to adversely affect the market
value of the securities.
|
§
|
As a finance subsidiary, MSFL has no independent operations and will have no independent assets.
As a finance subsidiary,
MSFL has no independent operations beyond the issuance and administration of its securities and will have no independent assets
available for distributions to holders of MSFL securities if they make claims in respect of such securities in a bankruptcy, resolution
or similar proceeding. Accordingly, any recoveries by such holders will be limited to those available under the related guarantee
by Morgan Stanley and that guarantee will rank
pari passu
with all other unsecured, unsubordinated obligations of Morgan
Stanley. Holders will have recourse only to a single claim against Morgan Stanley and its assets under the guarantee. Holders of
securities issued by MSFL should accordingly assume that in any such proceedings they would not have any priority over and should
be treated
pari passu
with the claims of other unsecured, unsubordinated creditors of Morgan Stanley, including holders
of Morgan Stanley-issued securities.
|
|
§
|
Reinvestment risk.
The term
of your investment in the securities may be shortened due to the automatic early redemption feature of the securities. If the securities
are redeemed prior to maturity, you will receive no more contingent monthly coupons and may be forced to invest in a lower interest
rate environment and may not be able to reinvest at comparable terms or returns.
However, under no circumstances
will the securities be redeemed in the six months of the term of the securities.
|
|
§
|
The antidilution adjustments the calculation agent is required to make do not cover every event that could affect the underlying
shares.
MS & Co., as calculation agent, will adjust the adjustment factors for certain events affecting the underlying
shares. However, the calculation agent will not make an adjustment for every event that can affect the underlying shares. If an
event occurs that does not require the calculation agent to adjust an adjustment factor, the market price of the
securities
may be materially and adversely affected.
|
|
§
|
The securities will not be listed on any securities exchange and secondary trading may be limited
,
and
accordingly, you should be willing to hold your securities for the entire 3-year term of the securities.
The securities
will not be listed on any securities exchange. Therefore, there may be little or no secondary market for the securities. MS &
Co. may, but is not obligated to, make a market in the securities and, if it once chooses to make a market, may cease doing so
at any time. When it does make a market, it will generally do so for transactions of routine secondary market size at prices based
on its estimate of the current value of the securities, taking into account its bid/offer spread, our credit spreads, market volatility,
the notional size of the proposed sale, the cost of unwinding any related hedging positions, the time remaining to maturity and
the likelihood that it will be able to resell the securities. Even if there is a secondary market, it may not provide enough liquidity
to allow you to trade or sell the securities easily. Since other broker-dealers may not participate significantly in the secondary
market for the securities, the price at which you may be able to trade your securities is likely to depend on the price, if any,
at which MS & Co. is willing to transact. If, at any time, MS & Co. were to cease making a market in the securities, it
is likely that there would be no secondary market for the securities. Accordingly, you should be willing to hold your securities
to maturity.
|
|
§
|
The rate we are willing to pay for securities of this type, maturity and issuance size is likely to be lower than the rate
implied by our secondary market credit spreads and advantageous to us. Both the lower rate and the inclusion of costs associated
with issuing, selling, structuring and hedging the securities in the original issue price reduce the economic terms of the securities,
cause the estimated value of the securities to be less than the original issue price and will adversely affect secondary market
prices.
Assuming no change in market conditions or any other relevant factors, the prices, if any, at which dealers, including
MS & Co., may be willing to purchase the securities in secondary market transactions will likely be significantly lower than
the original issue price, because secondary market prices will exclude the issuing, selling, structuring and hedging-related costs
that are included in the original issue price and borne by you and because the secondary market prices will reflect our secondary
market credit spreads and the bid-offer spread that any dealer would charge in a secondary market transaction of this type as well
as other factors.
|
The inclusion of the costs of issuing,
selling, structuring and hedging the securities in the original issue price and the lower rate we are willing to pay as issuer
make the economic terms of the securities less favorable to you than they otherwise would be.
However, because the costs associated
with issuing, selling, structuring and hedging the securities are not fully deducted upon issuance, for a period of up to 6 months
following the issue date, to the extent that MS & Co. may buy or sell the securities in the secondary market, absent changes
in market conditions, including those related to the underlying shares,
Morgan Stanley Finance LLC
Contingent Income Buffered Auto-Callable Securities due June 3, 2022, With 6-month Initial Non-Call Period
All Payments on the Securities Based on the Worst Performing of the SPDR
®
S&P
®
Biotech ETF and the VanEck Vectors
®
Gold Miners ETF
Principal at Risk Securities
and to our secondary market credit
spreads, it would do so based on values higher than the estimated value, and we expect that those higher values will also be reflected
in your brokerage account statements.
|
§
|
The estimated value of the securities is determined by reference to our pricing and valuation models, which may differ from
those of other dealers, and is not a maximum or minimum secondary market price.
These pricing and valuation models are proprietary
and rely in part on subjective views of certain market inputs and certain assumptions about future events, which may prove to be
incorrect. As a result, because there is no market-standard way to value these types of securities, our models may yield a higher
estimated value of the securities than those generated by others, including other dealers in the market, if they attempted to value
the securities. In addition, the estimated value on the pricing date does not represent a minimum or maximum price at which dealers,
including MS & Co., would be willing to purchase your securities in the secondary market (if any exists) at any time. The value
of your securities at any time after the date of this document will vary based on many factors that cannot be predicted with accuracy,
including our creditworthiness and changes in market conditions. See also “The market price will be influenced by many unpredictable
factors” above.
|
|
§
|
Adjustments to the underlying shares or the indices tracked by the underlying shares could adversely affect the value of
the securities.
The investment advisor to each of the underlying shares (SSGA Funds Management Inc. for the XBI Shares and
Van Eck Associates Corporation for the GDX Shares) seeks investment results that correspond generally to the price and yield performance,
before fees and expenses, of the relevant share underlying index. Pursuant to its investment strategy or otherwise, the investment
advisor may add, delete or substitute the stocks composing the respective underlying shares. Any of these actions could adversely
affect the price of the respective underlying shares and, consequently, the value of the securities. The publishers of the share
underlying indices are responsible for calculating and maintaining the share underlying indices. They may add, delete or substitute
the securities constituting the share underlying indices or make other methodological changes that could change the value of the
share underlying indices, and, consequently, the price of the underlying shares and the value of the securities. The publishers
of the share underlying indices may discontinue or suspend calculation or publication of a share underlying index at any time.
In these circumstances, the calculation agent will have the sole discretion to substitute a successor index that is comparable
to the discontinued share underlying index and will be permitted to consider indices that are calculated and published by the calculation
agent or any of its affiliates.
|
|
§
|
The performance and market price of either of the underlying shares, particularly during periods of market volatility, may
not correlate with the performance of its respective share underlying index, the performance of the component securities of such
share underlying index or the net asset value per share of such underlying shares.
The underlying shares do not fully
replicate their respective share underlying indices, and each may hold securities that are different than those included in its
respective share underlying index. In addition, the performance of each of the underlying shares will reflect additional
transaction costs and fees that are not included in the calculation of the share underlying indices. All of these factors
may lead to a lack of correlation between the performance of each of the underlying shares and its respective share underlying
index. In addition, corporate actions (such as mergers and spin-offs) with respect to the equity securities underlying each
of the underlying shares may impact the variance between the performance of each of the underlying shares and its respective share
underlying index. Finally, because the shares of each of the underlying shares are traded on an exchange and are subject
to market supply and investor demand, the market price of one share of each of the underlying shares may differ from the net asset
value per share of such underlying shares.
|
In particular, during periods of
market volatility, or unusual trading activity, trading in the securities underlying each of the underlying shares may be disrupted
or limited, or such securities may be unavailable in the secondary market. Under these circumstances, the liquidity of each
underlying shares may be adversely affected, market participants may be unable to calculate accurately the net asset value per
share of each of the underlying shares, and their ability to create and redeem shares of each of the underlying shares may be disrupted.
Under these circumstances, the market price of shares of each of the underlying shares may vary substantially from the net asset
value per share of each underlying share or the level of its respective share underlying index.
For all of the foregoing reasons,
the performance of each of the underlying shares may not correlate with the performance of its respective share underlying index,
the performance of the component securities of such share underlying index or the net asset value per share of such underlying
shares. Any of these events could materially and adversely affect the prices of each of the underlying shares and, therefore,
the value of the securities. Additionally, if market volatility or these events were to occur on the final observation date, the
calculation agent would maintain discretion to determine whether such market volatility or events have caused a market disruption
event to occur, and such determination would affect the
Morgan Stanley Finance LLC
Contingent Income Buffered Auto-Callable Securities due June 3, 2022, With 6-month Initial Non-Call Period
All Payments on the Securities Based on the Worst Performing of the SPDR
®
S&P
®
Biotech ETF and the VanEck Vectors
®
Gold Miners ETF
Principal at Risk Securities
payment at maturity of the securities.
If the calculation agent determines that no market disruption event has taken place, the payment at maturity would be based
solely on the published closing price per share of each of the underlying shares on the final observation date, even if either
of the underlying shares is underperforming its respective share underlying index or the component securities of such share underlying
index and/or trading below the net asset value per share of such underlying shares.
|
§
|
Not equivalent to investing in the underlying shares or the stocks
composing the share underlying indices.
Investing in the securities is not equivalent to
investing in the underlying shares, the share underlying indices or the stocks that constitute the share underlying indices. Investors
in the securities will not have voting rights or rights to receive dividends or other distributions or any other rights with respect
to the underlying shares or the stocks that constitute the share underlying indices.
|
|
§
|
Hedging and trading activity by our affiliates could potentially affect the value of the securities.
One or more of
our affiliates and/or third-party dealers have carried out, and will continue to carry out, hedging activities related to the securities
(and to other instruments linked to the underlying shares and the share underlying indices), including trading in the underlying
shares. As a result, these entities may be unwinding or adjusting hedge positions during the term of the securities, and the hedging
strategy may involve greater and more frequent dynamic adjustments to the hedge as the final observation date approaches. Some
of our affiliates also trade the underlying shares and other financial instruments related to the underlying shares and the share
underlying indices on a regular basis as part of their general broker-dealer and other businesses. Any of these hedging or trading
activities on or prior to the pricing date could have increased the initial share price of either of the underlying shares and,
therefore, could have increased (i) the value at or above which such underlying shares must close on the redemption determination
dates so that the securities are redeemed prior to maturity for the early redemption payment (depending also on the performance
of the other underlying shares), (ii) the coupon barrier level for such underlying shares, which is the value at or above which
the underlying shares must close on the observation dates so that you receive a contingent monthly coupon on the securities (depending
also on the performance of the other underlying shares), and (iii) the value at or above which such underlying shares must close
on the final observation date so that you are not exposed to the negative performance of the worst performing underlying shares
at maturity (depending also on the performance of the other underlying shares). Additionally, such hedging or trading activities
during the term of the securities could potentially affect the value of either of the underlying shares on the redemption determination
dates and the observation dates and, accordingly, whether we redeem the securities prior to maturity, whether we pay a contingent
monthly coupon on the securities and the amount of cash you will receive at maturity.
|
|
§
|
The calculation agent, which is a subsidiary of Morgan Stanley and an affiliate of MSFL, will make determinations with respect
to the securities.
As calculation agent, MS & Co. has determined the initial share prices and the coupon barrier levels
and will determine the final share prices, the payment at maturity, whether you receive a contingent monthly coupon on each coupon
payment date and/or at maturity, whether the securities will be redeemed on any early redemption date, whether a market disruption
event has occurred and whether to make any adjustments to the adjustment factors. Moreover, certain determinations made by MS &
Co., in its capacity as calculation agent, may require it to exercise discretion and make subjective judgments, such as with respect
to the occurrence or non-occurrence of market disruption events or calculation of the determination closing price in the event
of a market disruption event. These potentially subjective determinations may affect the payout to you upon an automatic early
redemption or at maturity. For further information regarding these types of determinations, see “Description of Auto-Callable
Securities—Auto-Callable Securities Linked to Underlying Shares” and “—Calculation Agent and Calculations”
in the accompanying product supplement. In addition, MS & Co. has determined the estimated value of the securities on the pricing
date.
|
|
§
|
The U.S. federal income tax consequences of an investment in the securities are uncertain.
There is no direct legal
authority as to the proper treatment of the securities for U.S. federal income tax purposes, and, therefore, significant aspects
of the tax treatment of the securities are uncertain.
|
Please read the discussion under
“Additional Information—Tax considerations” in this document concerning the U.S. federal income tax consequences
of an investment in the securities. We intend to treat a security for U.S. federal income tax purposes as a single financial contract
that provides for a coupon that will be treated as gross income to you at the time received or accrued, in accordance with your
regular method of tax accounting. Under this treatment, the ordinary income treatment of the coupon payments, in conjunction with
the capital loss treatment of any loss recognized upon the sale, exchange or settlement of the securities, could result in adverse
tax consequences to holders of the securities because the deductibility of capital losses is subject to limitations. We do not
plan to request a ruling from the Internal Revenue Service (the “IRS”) regarding the tax treatment of the securities,
and the IRS or a court may not agree with the tax treatment
Morgan Stanley Finance LLC
Contingent Income Buffered Auto-Callable Securities due June 3, 2022, With 6-month Initial Non-Call Period
All Payments on the Securities Based on the Worst Performing of the SPDR
®
S&P
®
Biotech ETF and the VanEck Vectors
®
Gold Miners ETF
Principal at Risk Securities
described herein. If the IRS were
successful in asserting an alternative treatment for the securities, the timing and character of income or loss on the securities
might differ significantly from the tax treatment described herein. For example, under one possible treatment, the IRS could seek
to recharacterize the securities as debt instruments. In that event, U.S. Holders (as defined below) would be required to accrue
into income original issue discount on the securities every year at a “comparable yield” determined at the time of
issuance (as adjusted based on the difference, if any, between the actual and the projected amount of any contingent payments on
the securities) and recognize all income and gain in respect of the securities as ordinary income. The risk that financial instruments
providing for buffers, triggers or similar downside protection features, such as the securities, would be recharacterized as debt
is greater than the risk of recharacterization for comparable financial instruments that do not have such features.
Non-U.S. Holders (as defined
below) should note that we currently intend to withhold on any coupon paid to Non-U.S. Holders generally at a rate of 30%, or at
a reduced rate specified by an applicable income tax treaty under an “other income” or similar provision, and will
not be required to pay any additional amounts with respect to amounts withheld.
In 2007, the U.S. Treasury Department
and the IRS released a notice requesting comments on the U.S. federal income tax treatment of “prepaid forward contracts”
and similar instruments. While it is not clear whether the securities would be viewed as similar to the prepaid forward contracts
described in the notice, it is possible that any Treasury regulations or other guidance promulgated after consideration of these
issues could materially and adversely affect the tax consequences of an investment in the securities, possibly with retroactive
effect. The notice focuses on a number of issues, the most relevant of which for holders of the securities are the character and
timing of income or loss and the degree, if any, to which income realized by non-U.S. investors should be subject to withholding
tax. Both U.S. and Non-U.S. Holders should consult their tax advisers regarding the U.S. federal income tax consequences of an
investment in the securities, including possible alternative treatments, the issues presented by this notice and any tax consequences
arising under the laws of any state, local or non-U.S. taxing jurisdiction.
Morgan Stanley Finance LLC
Contingent Income Buffered Auto-Callable Securities due June 3, 2022, With 6-month Initial Non-Call Period
All Payments on the Securities Based on the Worst Performing of the SPDR
®
S&P
®
Biotech ETF and the VanEck Vectors
®
Gold Miners ETF
Principal at Risk Securities
SPDR
®
S&P
®
Biotech ETF Overview
The SPDR
®
S&P
®
Biotech
ETF is an exchange-traded fund managed by SSGA Funds Management, Inc., which seeks to provide investment results that correspond
generally to the price and yield performance, before fees and expenses, of the S&P Biotechnology Select Industry
TM
Index.
SPDR
®
Series Trust (the “Trust”) is a registered investment company that consists of numerous separate
investment portfolios, including the SPDR
®
S&P
®
Biotech ETF. Information provided to
or filed with the Securities and Exchange Commission (the “Commission”) by the Trust pursuant to the Securities Act
of 1933 and the Investment Company Act of 1940 can be located by reference to Commission file numbers 333-57793 and 811-08839,
respectively, through the Commission’s website at www.sec.gov. In addition, information may be obtained from other publicly
available sources.
Neither the issuer nor the agent makes any representation
that any such publicly available information regarding the
SPDR
®
S&P
®
Biotech ETF
is accurate or complete.
Information as of market close on May 28,
2019:
Ticker Symbol:
|
XBI UP
|
Current Stock Price:
|
$82.03
|
52 Weeks Ago:
|
$92.47
|
52 Week High (on 6/20/2018):
|
$101.15
|
52 Week Low (on 12/24/2018):
|
$65.42
|
The following graph sets forth the daily closing
values of the XBI Shares for the period from January 1, 2014 through May 28, 2019. The related table sets forth the published high
and low closing prices, as well as the end-of-quarter closing prices, of the XBI Shares for each quarter in the same period. The
closing price of the XBI Shares on May 28, 2019 was $82.03. We obtained the information in the table and graph below from Bloomberg
Financial Markets, without independent verification. The historical performance of the XBI Shares should not be taken as an indication
of its future performance, and no assurance can be given as to the price of the XBI Shares at any time, including on the redemption
determination dates or the observation dates.
Shares of the SPDR
®
S&P
®
Biotech ETF – Daily Closing Prices
January 1, 2014 to May 28, 2019
|
|
Morgan Stanley Finance LLC
Contingent Income Buffered Auto-Callable Securities due June 3, 2022, With 6-month Initial Non-Call Period
All Payments on the Securities Based on the Worst Performing of the SPDR
®
S&P
®
Biotech ETF and the VanEck Vectors
®
Gold Miners ETF
Principal at Risk Securities
SPDR
®
S&P
®
Biotech ETF (CUSIP: 78464A870)
|
High ($)
|
Low ($)
|
Period End ($)
|
2014
|
|
|
|
First Quarter
|
56.90
|
42.97
|
47.49
|
Second Quarter
|
51.35
|
40.27
|
51.35
|
Third Quarter
|
54.30
|
44.87
|
51.99
|
Fourth Quarter
|
63.45
|
48.48
|
62.21
|
2015
|
|
|
|
First Quarter
|
79.33
|
61.43
|
75.17
|
Second Quarter
|
86.57
|
68.78
|
84.08
|
Third Quarter
|
90.36
|
60.02
|
62.25
|
Fourth Quarter
|
72.62
|
61.16
|
70.08
|
2016
|
|
|
|
First Quarter
|
67.83
|
45.73
|
51.66
|
Second Quarter
|
59.87
|
49.55
|
54.09
|
Third Quarter
|
68.83
|
55.11
|
66.29
|
Fourth Quarter
|
68.13
|
53.31
|
59.19
|
2017
|
|
|
|
First Quarter
|
72.32
|
59.59
|
69.34
|
Second Quarter
|
80.31
|
66.84
|
77.18
|
Third Quarter
|
86.57
|
74.47
|
86.57
|
Fourth Quarter
|
88.51
|
79.95
|
84.87
|
2018
|
|
|
|
First Quarter
|
97.03
|
85.31
|
87.73
|
Second Quarter
|
101.15
|
82.90
|
95.19
|
Third Quarter
|
100.84
|
93.08
|
95.87
|
Fourth Quarter
|
94.90
|
65.42
|
71.75
|
2019
|
|
|
|
First Quarter
|
91.92
|
71.21
|
90.54
|
Second Quarter (through May 28, 2019)
|
93.80
|
80.41
|
82.03
|
This document relates only to the securities referenced hereby
and does not relate to the XBI Shares. We have derived all disclosures contained in this document regarding the Trust
from the publicly available documents described above. In connection with the offering of the securities, neither we
nor the agent has participated in the preparation of such documents or made any due diligence inquiry with respect to the Trust. Neither
we nor the agent makes any representation that such publicly available documents or any other publicly available information regarding
the Trust is accurate or complete. Furthermore, we cannot give any assurance that all events occurring prior to the
date hereof (including events that would affect the accuracy or completeness of the publicly available documents described above)
that would affect the trading price of the XBI Shares (and therefore the price of the XBI Shares at the time we priced the securities)
have been publicly disclosed. Subsequent disclosure of any such events or the disclosure of or failure to disclose material
future events concerning the Trust could affect the value received with respect to the securities and therefore the value of the
securities.
Neither we nor any of our affiliates makes any representation
to you as to the performance of the XBI Shares.
We and/or our affiliates may presently or from time to time engage
in business with the Trust. In the course of such business, we and/or our affiliates may acquire non-public information
with respect to the Trust, and neither we nor any of our affiliates undertakes to disclose any such information to you. In
addition, one or more of our affiliates may publish research reports with respect to the XBI Shares. The statements
in the preceding two sentences are not intended to affect the rights of investors in the securities under the securities laws. As
a purchaser of the securities, you should undertake an independent investigation of the Trust as in your judgment is appropriate
to make an informed decision with respect to an investment linked to the XBI Shares.
“S&P
®
”, “SPDR
®
”
and “S&P Biotechnology Select Industry
TM
Index” are trademarks of Standard & Poor’s Financial
Services LLC (“S&P”), an affiliate of The McGraw-Hill Companies, Inc. (“MGH”). The securities are not
sponsored, endorsed, sold, or promoted by S&P, MGH or the Trust. S&P, MGH and the Trust make no representations or warranties
to the owners of the securities or any member of the public regarding the advisability of investing in the Securities. S&P,
MGH and the the Trust have no obligation or liability in connection with the operation, marketing, trading or sale of the securities.
The S&P
Biotechnology Select Industry
TM
Index.
The S&P Biotechnology Select Industry
TM
Index
(Bloomberg ticker SPSIBI) is managed by S&P Dow Jones Indices LLC and is a modified equally weighted index that is designed
to measure the performance of stocks in the S&P Total Market Index that are classified under the Global Industry Classification
Standard (“GICS
®
”) biotechnology sub-industry.
Morgan Stanley Finance LLC
Contingent Income Buffered Auto-Callable Securities due June 3, 2022, With 6-month Initial Non-Call Period
All Payments on the Securities Based on the Worst Performing of the SPDR
®
S&P
®
Biotech ETF and the VanEck Vectors
®
Gold Miners ETF
Principal at Risk Securities
VanEck Vectors
®
Gold Miners ETF Overview
The VanEck Vectors
®
Gold Miners ETF is an exchange-traded
fund managed by Van Eck Associates Corporation (“Van Eck”), a registered investment company, that seeks investment
results that correspond generally to the price and yield performance, before fees and expenses, of the NYSE Arca Gold Miners Index.
Information provided to or filed with the Securities and Exchange Commission (“the Commission”) by Van Eck pursuant
to the Securities Act of 1933 and the Investment Company Act of 1940 can be located by reference to Commission file numbers 333-123257
and 811-10325, respectively, through the Commission’s website at.www.sec.gov. In addition, information may be obtained from
other publicly available sources.
Neither the issuer nor the agent makes any representation that any such publicly available
information regarding the VanEck Vectors
®
Gold Miners ETF is accurate or complete.
Information as of market close on May 28, 2019:
Ticker Symbol:
|
GDX UP
|
Current Share Price:
|
$20.42
|
52 Weeks Ago:
|
$22.15
|
52 Week High (on 2/20/2019):
|
$23.36
|
52 Week Low (on 9/11/2018):
|
$17.57
|
The following graph sets forth the daily closing values of the
GDX Shares for the period from January 1, 2014 through May 28, 2019. The related table sets forth the published high and low closing
prices, as well as the end-of-quarter closing prices, of the GDX Shares for each quarter in the same period. The closing price
of the GDX Shares on May 28, 2019 was $20.42. We obtained the information in the table and graph below from Bloomberg Financial
Markets, without independent verification. The historical performance of the GDX Shares should not be taken as an indication of
its future performance, and no assurance can be given as to the price of the GDX Shares at any time, including on the redemption
determination dates or the observation dates.
Shares of the VanEck
Vectors
®
Gold Miners ETF — Daily Closing Prices
January 1, 2014 to May
28, 2019
|
|
Morgan Stanley Finance LLC
Contingent Income Buffered Auto-Callable Securities due June 3, 2022, With 6-month Initial Non-Call Period
All Payments on the Securities Based on the Worst Performing of the SPDR
®
S&P
®
Biotech ETF and the VanEck Vectors
®
Gold Miners ETF
Principal at Risk Securities
VanEck Vectors
®
Gold Miners ETF (CUSIP 57060U100)
|
High ($)
|
Low ($)
|
Period End ($)
|
2014
|
|
|
|
First Quarter
|
27.73
|
21.27
|
23.60
|
Second Quarter
|
26.45
|
22.04
|
26.45
|
Third Quarter
|
27.46
|
21.35
|
21.35
|
Fourth Quarter
|
21.94
|
16.59
|
18.38
|
2015
|
|
|
|
First Quarter
|
22.94
|
17.67
|
18.24
|
Second Quarter
|
20.82
|
17.76
|
17.76
|
Third Quarter
|
17.85
|
13.04
|
13.74
|
Fourth Quarter
|
16.90
|
13.08
|
13.72
|
2016
|
|
|
|
First Quarter
|
20.86
|
12.47
|
19.98
|
Second Quarter
|
27.70
|
19.53
|
27.70
|
Third Quarter
|
31.32
|
25.45
|
26.43
|
Fourth Quarter
|
25.96
|
18.99
|
20.92
|
2017
|
|
|
|
First Quarter
|
25.57
|
21.14
|
22.81
|
Second Quarter
|
24.57
|
21.10
|
22.08
|
Third Quarter
|
25.49
|
21.21
|
22.96
|
Fourth Quarter
|
23.84
|
21.42
|
23.24
|
2018
|
|
|
|
First Quarter
|
24.60
|
21.27
|
21.98
|
Second Quarter
|
23.06
|
21.81
|
22.31
|
Third Quarter
|
22.68
|
17.57
|
18.52
|
Fourth Quarter
|
21.09
|
18.39
|
21.09
|
2019
|
|
|
|
First Quarter
|
23.36
|
20.31
|
22.42
|
Second Quarter (through May 28, 2019)
|
22.82
|
20.17
|
20.42
|
This document relates only to the securities referenced hereby
and does not relate to the GDX Shares. We have derived all disclosures contained in this document regarding Van Eck from the publicly
available documents described above. In connection with the offering of the securities, neither we nor the agent has participated
in the preparation of such documents or made any due diligence inquiry with respect to Van Eck. Neither we nor the agent makes
any representation that such publicly available documents or any other publicly available information regarding Van Eck is accurate
or complete. Furthermore, we cannot give any assurance that all events occurring prior to the date hereof (including events that
would affect the accuracy or completeness of the publicly available documents described above) that would affect the trading price
of the GDX Shares (and therefore the price of the GDX Shares at the time we priced the securities) have been publicly disclosed.
Subsequent disclosure of any such events or the disclosure of or failure to disclose material future events concerning Van Eck
could affect the value received with respect to the securities and therefore the value of the securities.
Neither we nor any of our affiliates makes any representation
to you as to the performance of the GDX Shares.
We and/or our affiliates may presently or from time to time engage
in business with Van Eck. In the course of such business, we and/or our affiliates may acquire non-public information with respect
to Van Eck, and neither we nor any of our affiliates undertakes to disclose any such information to you. In addition, one or more
of our affiliates may publish research reports with respect to the GDX Shares. The statements in the preceding two sentences are
not intended to affect the rights of investors in the securities under the securities laws. As a purchaser of the securities, you
should undertake an independent investigation of Van Eck as in your judgment is appropriate to make an informed decision with respect
to an investment linked to the GDX Shares.
The securities are not sponsored, endorsed, sold, or promoted
by Van Eck. Van Eck makes no representations or warranties to the owners of the securities or any member of the public regarding
the advisability of investing in the securities. Van Eck has no obligation or liability in connection with the operation, marketing,
trading or sale of the securities.
The NYSE Arca
Gold Miners Index.
The NYSE Arca Gold Miners Index is a modified market capitalization
weighted index comprised of publicly traded companies involved primarily in the mining of gold and silver. The NYSE Arca Gold Miners
Index includes common stocks, American depositary receipts or global depositary receipts of selected companies involved in the
mining for gold and silver ore and are listed for trading and electronically quoted on a major stock market that is accessible
by foreign investors. For additional information about the NYSE Arca Gold Miners Index, please see the information set forth under
“NYSE Arca Gold Miners Index” in the accompanying index supplement.
Morgan Stanley Finance LLC
Contingent Income Buffered Auto-Callable Securities due June 3, 2022, With 6-month Initial Non-Call Period
All Payments on the Securities Based on the Worst Performing of the SPDR
®
S&P
®
Biotech ETF and the VanEck Vectors
®
Gold Miners ETF
Principal at Risk Securities
Additional Terms of the Securities
Please read this information in conjunction with the summary
terms on the front cover of this document.
Additional Terms:
|
If the terms described herein are inconsistent with those described in the accompanying product supplement, index supplement or prospectus, the terms described herein shall control.
|
Interest period:
|
The monthly period from and including the original issue date (in the case of the first interest period) or the previous scheduled coupon payment date, as applicable, to but excluding the following scheduled coupon payment date, with no adjustment for any postponement thereof.
|
Record date:
|
The record date for each coupon payment date shall be the date one business day prior to such scheduled coupon payment date;
provided
, however, that any coupon payable at maturity (or upon early redemption) shall be payable to the person to whom the payment at maturity or early redemption payment, as the case may be, shall be payable.
|
Share underlying indices:
|
With respect to the XBI Shares, the S&P Biotechnology Select
Industry
TM
Index
With respect to the GDX Shares,
the NYSE Arca Gold Miners Index
|
Share underlying index publishers:
|
With respect to the XBI Shares, S&P Dow Jones Indices LLC,
or any successor thereof.
With respect to the GDX Shares, NYSE Arca, or any successor thereof.
|
Day count convention:
|
Interest will be computed on the basis of a 360-day year of twelve 30-day months.
|
Postponement of coupon payment dates (including the maturity date) and early redemption dates:
|
If any observation date or redemption determination date is postponed due to a non-trading day or certain market disruption events with respect to either of the underlying shares so that it falls less than two business days prior to the relevant scheduled coupon payment date (including the maturity date) or early redemption date, as applicable, the coupon payment date (or the maturity date) or the early redemption date will be postponed to the second business day following that observation date or redemption determination date as postponed, and no adjustment will be made to any coupon payment, early redemption payment or payment at maturity made on that postponed date.
|
Trustee:
|
The Bank of New York Mellon
|
Calculation agent:
|
MS & Co.
|
Issuer notices to registered security holders, the trustee and the depositary:
|
In the event that the maturity date is postponed due to postponement
of the final observation date, the issuer shall give notice of such postponement and, once it has been determined, of the date
to which the maturity date has been rescheduled (i) to each registered holder of the securities by mailing notice of such postponement
by first class mail, postage prepaid, to such registered holder’s last address as it shall appear upon the registry books,
(ii) to the trustee by facsimile, confirmed by mailing such notice to the trustee by first class mail, postage prepaid, at its
New York office and (iii) to The Depository Trust Company (the “depositary”) by telephone or facsimile confirmed by
mailing such notice to the depositary by first class mail, postage prepaid. Any notice that is mailed to a registered holder of
the securities in the manner herein provided shall be conclusively presumed to have been duly given to such registered holder,
whether or not such registered holder receives the notice. The issuer shall give such notice as promptly as possible, and in no
case later than (i) with respect to notice of postponement of the maturity date, the business day immediately preceding the scheduled
maturity date and (ii) with respect to notice of the date to which the maturity date has been rescheduled, the business day immediately
following the final observation date as postponed.
In the event that the securities are subject to early redemption,
the issuer shall, (i) on the business day following the applicable redemption determination date, give notice of the early redemption
and the early redemption payment, including specifying the payment date of the amount due upon the early redemption, (x) to each
registered holder of the securities by mailing notice of such early redemption by first class mail, postage prepaid, to such registered
holder’s last address as it shall appear upon the registry books, (y) to the trustee by facsimile confirmed by mailing such
notice to the trustee by first class mail, postage prepaid, at its New York office and (z) to the depositary by telephone or facsimile
confirmed by mailing such notice to the depositary by first class mail, postage prepaid, and (ii) on or prior to the early redemption
date, deliver the aggregate cash amount due with respect to the securities to the trustee for delivery to the depositary, as holder
of the securities. Any notice that is mailed to a registered holder of the securities in the manner herein provided shall be conclusively
presumed to have been duly given to such registered holder, whether or not such registered holder receives the notice. This notice
shall be given by the issuer or, at the issuer’s request, by the trustee in the name and at the expense of the issuer, with
any such request to be accompanied by a copy of the notice to be given.
The issuer shall, or shall cause the calculation agent to, (i)
provide written notice to the trustee, on which notice the trustee may conclusively rely, and to the depositary of the amount of
cash to be delivered as monthly coupon with respect to each security on or prior to 10:30 a.m. (New York City time) on the business
day preceding each coupon payment date, and (ii) deliver the aggregate cash amount due with respect to the monthly coupon to the
trustee for delivery to the depositary, as holder of the securities, on the applicable coupon payment date.
The issuer shall, or shall cause the calculation agent to, (i)
provide written notice to the trustee,
|
Morgan Stanley Finance LLC
Contingent Income Buffered Auto-Callable Securities due June 3, 2022, With 6-month Initial Non-Call Period
All Payments on the Securities Based on the Worst Performing of the SPDR
®
S&P
®
Biotech ETF and the VanEck Vectors
®
Gold Miners ETF
Principal at Risk Securities
|
on which notice the trustee may conclusively rely, and to the depositary of the amount of cash to be delivered with respect to each stated principal amount of the securities, on or prior to 10:30 a.m. (New York City time) on the business day preceding the maturity date, and (ii) deliver the aggregate cash amount due with respect to the securities to the trustee for delivery to the depositary, as holder of the securities, on the maturity date.
|
Morgan Stanley Finance LLC
Contingent Income Buffered Auto-Callable Securities due June 3, 2022, With 6-month Initial Non-Call Period
All Payments on the Securities Based on the Worst Performing of the SPDR
®
S&P
®
Biotech ETF and the VanEck Vectors
®
Gold Miners ETF
Principal at Risk Securities